Zydus Cadila has received an establishment inspection report from the US health regulator for its manufacturing facility at Pharma SEZ at Ahmedabad.
The plant had completed the United States Food and Drug Administration (USFDA) audit from January 16-24, 2017, Zydus Cadila said in a statement today.
The drug firm's “formulations manufacturing facility at Pharma SEZ, Ahmedabad has received an establishment inspection report (EIR) from the USFDA signifying the successful closure of the audit”, it added.
Shares of Cadila Healthcare, the listed entity of Zydus Group, were trading at Rs 499.75, down 0.26 per cent, on the BSE.